Blythe Sather

Title: Blythe Sather: Innovator in Immunotherapy

Introduction

Blythe Sather is a notable inventor based in South San Francisco, CA (US). He has made significant contributions to the field of immunotherapy, particularly through his work on nucleotide sequences and chimeric antigen receptors. With a total of 2 patents, Sather is recognized for his innovative approaches to treating diseases such as cancer.

Latest Patents

Sather's latest patents include groundbreaking work on codon-optimized nucleotide sequences encoding an AP-1 transcription factor. This patent discloses polynucleotides that comprise a nucleotide sequence encoding an AP-1 transcription factor, specifically c-Jun. The invention also includes additional nucleotide sequences that can encode various functional domains, which are crucial for developing therapeutic applications. Another significant patent focuses on ROR1 targeting chimeric antigen receptors. This disclosure relates to polynucleotides encoding a chimeric polypeptide that includes a c-Jun polypeptide and a ROR1-binding protein. The overexpression of c-Jun in CAR T cells is designed to enhance their properties, particularly in reducing exhaustion.

Career Highlights

Blythe Sather is currently employed at Lyell Immunopharma, Inc., where he continues to advance his research in immunotherapy. His work is pivotal in developing innovative treatments that leverage the body's immune system to combat cancer.

Collaborations

Sather collaborates with talented individuals such as Spencer Park and Queenie Vong, who contribute to the innovative environment at Lyell Immunopharma.

Conclusion

Blythe Sather's contributions to immunotherapy through his patents and collaborative efforts highlight his role as a leading inventor in the field. His work promises to pave the way for new therapeutic strategies in the fight against cancer.